ERGO Stock Overview

Engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. More details

ERGO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($3K)

Latest financial reports are more than a year old

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Entia Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Entia Biosciences
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0002
52 Week Low	US$0.000001
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-99.69%
5 Year Change	-98.75%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ERGO	US Personal Products	US Market
7D	0%	3.6%	1.2%
1Y	n/a	-15.2%	12.5%

Return vs Industry: Insufficient data to determine how ERGO performed against the US Personal Products industry.

Return vs Market: Insufficient data to determine how ERGO performed against the US Market.

Price Volatility

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	n/a
Personal Products Industry Average Movement	9.2%
Market Average Movement	8.0%
10% most volatile stocks in US Market	17.2%
10% least volatile stocks in US Market	4.1%

Stable Share Price: ERGO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ERGO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	n/a	Timothy Timmins	www.entiabio.com

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company’s portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant.

Entia Biosciences, Inc. Fundamentals Summary

How do Entia Biosciences's earnings and revenue compare to its market cap?
ERGO fundamental statistics
Market cap	US$3.41k
Earnings (TTM)	-US$1.40m
Revenue (TTM)	US$265.47k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ERGO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ERGO income statement (TTM)
Revenue	US$265.47k
Cost of Revenue	US$91.50k
Gross Profit	US$173.97k
Other Expenses	US$1.57m
Earnings	-US$1.40m

Last Reported Earnings

Dec 31, 2016

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ERGO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/29 07:03
End of Day Share Price	2025/05/02 00:00
Earnings	2016/12/31
Annual Earnings	2016/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Entia Biosciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.